Author

Mark Daniel Rutstein

Observed names: M. D. Rutstein, M. Rutstein, M.D. Rutstein, Mark D. Rutstein, Mark Rutstein

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Indiana University Health, Brigham and Women's Hospital, Tufts Medical Center, Amgen (United States), Harvard University, Bayer (United States), University of Massachusetts Chan Medical School, Eli Lilly (United States), McLean Hospital, Bristol-Myers Squibb (United States), Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

OpenAlex ID: A5050345282

Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats

2000 · Susan L. Andersen, Andrew T. Thompson, et al. · Synapse · 475

Sex differences in dopamine receptor overproduction and elimination

1997 · Susan L. Andersen, Mark Rutstein, et al. · Neuroreport · 316

Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database

2009 · W. Marieke Schoonen, Gena Kucera, et al. · British Journal of Haematology · 306

PDF

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

2009 · David J. Kuter, Ghulam J. Mufti, et al. · Blood · 183

Pharmacoepidemiology of Anemia in Kidney Transplant Recipients

2004 · Wolfgang C. Winkelmayer, Reshma Kewalramani, et al. · Journal of the American Society of Nephrology · 135

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

2019 · Guru Sonpavde, Andrea Necchi, et al. · Future Oncology · 95

PDF

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences

2008 · Susan D. Mathias, Sue K. Gao, et al. · Current Medical Research and Opinion · 33

Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

2015 · Michael Teufel, Susanne Schwenke, et al. · Journal of Clinical Oncology · 26

A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).

2019 · Guru Sonpavde, Andrea Necchi, et al. · Journal of Clinical Oncology · 9

Analysis of plasma protein biomarkers from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC).

2016 · Michael Teufel, Joachim Kalmus, et al. · Journal of Clinical Oncology · 9

A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162).

2012 · Richard T. Penson, Kathleen N. Moore, et al. · Journal of Clinical Oncology · 9

9209 Safety of romiplostim for treatment of severe chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma receiving multi-cycle chemotherapy: results from an open-label dose- and schedule-finding study

2009 · M. Fanale, P. Stiff, et al. · European Journal of Cancer Supplements · 9

Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).

2008 · Howard Liebman, David Henry, et al. · Blood · 9

A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.

2019 · Noah M. Hahn, Sam S. Chang, et al. · Journal of Clinical Oncology · 8

PD-003 Analysis of single-nucleotide polymorphisms (SNPs) in the phase 3 CORRECT trial of regorafenib vs placebo in patients with metastatic colorectal cancer (mCRC)

2016 · D. Lambrechts, K. Koechert, et al. · Annals of Oncology · 8

A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).

2012 · Axel Grothey, Josep Tabernero, et al. · Journal of Clinical Oncology · 8

Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).

2011 · L. T. Vahdat, K. Miller, et al. · Journal of Clinical Oncology · 7

2013 Analysis of biomarkers in circulating tumor DNA from the phase 3 CONCUR study of regorafenib in Asian patients with metastatic colorectal cancer (mCRC): Correlation with clinical outcome

2015 · M. Teufel, J. Kalmus, et al. · European Journal of Cancer · 6

A phase (Ph) Ib study of irinotecan (IRI), levofolinate (LV), and 5-fluorouracil (5-FU) (FOLFIRI) plus ramucirumab (RAM; IMC-1121B) drug product in Japanese (JP) patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (CP12-1029/NCT01286818).

2013 · Takayuki Yoshino, Kentaro Yamazaki, et al. · Journal of Clinical Oncology · 5

Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies

2022 · Leah Burns, Robert Kalesnik-Orszulak, et al. · Advances in Therapy · 4

PDF

A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

2019 · J.A. Witjes, J. Gschwend, et al. · European Urology Supplements · 4

Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)

2016 · M. Reck, L. Horn, et al. · Annals of Oncology · 4

PDF

Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

2011 · R. E. Martell, E. G. Chiorean, et al. · Journal of Clinical Oncology · 4

Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP).

2008 · Davi d J Kuter, Ghulam Mufti, et al. · Blood · 4

Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.

2012 · Daniel Peter Petrylak, Kim N. Chi, et al. · Journal of Clinical Oncology · 3

Works count: 33

Citation count: 1,682

H-index: 9

I10-index: 8